1549812-25-0

Basic information

• Product Name: (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester
• Synonyms: (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester
• CAS NO: 1549812-25-0
• Molecular Weight: 408.455
• Mol File: 1549812-25-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester(1549812-25-0)
• EPA Substance Registry System: (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester(1549812-25-0)

Safety Data

• Hazardous Substances Data: 1549812-25-0(Hazardous Substances Data)

Upstream product

• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 
• 1549812-23-8 3-methoxy-4-(methylamino)-5-nitrobenzoic acid 
• 1549812-20-5 methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate 
• 63603-09-8 methyl 4-chloro-3-methoxy-5-nitrobenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 42590-00-1 4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester 

Relevant articles and documents

Peptidylarginine deiminase inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I): wherein; R1 is hydrogen or C1-6alkyl;R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy;R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl;R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6 alkyl;A is C—R5 or N;B is C—R6 or N;D is C—R7 or N;with the proviso that at least one of A, B, and D, is N;R5 is hydrogen or C1-6alkyl;R6 is hydrogen or C1-6alkyl;R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy;R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen;R9 is hydrogen or hydroxy;R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.